黄连素抑制FSP27基因表达改善2型糖尿病地鼠内脏白色脂肪组织胰岛素抵抗的研究

摘要：目的 研究黄连素（BBR）对2型糖尿病（T2DM）中国地鼠内脏白色脂肪组织（VWAT）中脂肪特异蛋白27（FSP27）和PR结构域蛋白16 （PRDM16）信号通路基因mRNA表达的影响并探讨相关机制。方法 以高脂饮食诱导肥胖胰岛素抵抗（OIR）地鼠模型,然后给予小剂量链脲菌素建立T2DM地鼠模型,对照组喂以普通饲料。造模完成后随机分成对照组、OIR组、肥胖T2DM组和T2DM BBR组。BBR治疗9周后,应用实时定量PCR方法检测各组地鼠VWAT中FSP27和PRDM16信号通路及其靶基因的mRNA表达改变。结果 与对照组相比,OIR组和肥胖T2DM组地鼠VWAT中PRDM16、CtBP-1、CtBP-2、C/EBPβ、PPARγ、PGC1α、PGC-1β及棕脂组织特异基因UCP-1、Cidea、Elovl3、PPARα及Acox、Cpt1和Acadm的mRNA表达降低,而FSP27和白脂组织特异基因Resistin、MEST和Serpina3k的mRNA表达增加。BBR治疗降低肥胖T2DM组地鼠VWAT中FSP27的表达而增强PRDM16信号通路效应,诱导棕脂组织特异基因mRNA的表达,诱导VWAT棕色化基因表型,改善脂诱性胰岛素抵抗。结论 BBR降低FSP27表达而增加PRDM16的表达与其诱导VWAT棕色化的分子机制相关,有助于增强产热耗能, 改善VWAT的异常脂代谢,改善FIVWATIR,恢复VWAT的功能。     

黄连素对2型糖尿病地鼠内脏脂肪组织RIP140调控通路基因mRNA表达的影响

目的：研究黄连素（BBR）对肥胖2型糖尿病（OT2DM）中国地鼠内脏白色脂肪组织（VWAT）中受体相互作用蛋白140（Receptor-interacting protein 140,RIP140）/PR结构域蛋白16 （PR domain containing 16,PRDM16） 信号通路基因mRNA表达的影响及相关机制。方法：以高脂饮食诱导肥胖胰岛素抵抗（OIR）地鼠模型,然后给予小剂量链脲菌素（STZ）建立OT2DM地鼠模型。造模完成后随机分成对照组、OIR组、OT2DM组和OT2DM BBR治疗组。BBR治疗9周,应用real-time RT-PCR技术检测各组地鼠VWAT中RIP140/PRDM16信号通路基因mRNA表达改变。结果：模型地鼠VWAT中RIP140、PKCε、PRMT1、Exportin1和白脂组织特异基因Resistin和Serpina3k的mRNA表达增加,而PRDM16、CtBP-1、CtBP-2、C/EBPβ、PPARγ、PGC-1α、PGC-1β、Gyk、GPDH、AQP7、GLUT4及棕脂组织特异基因UCP-1、Cidea、Elovl3和PPARα的mRNA表达降低。BBR治疗抑制VWAT中RIP140调控通路,诱导PRDM16信号通路,诱导棕脂组织特异基因mRNA的表达,抑制白色脂肪选择性基因的表达,诱导VWAT棕色化,改善脂诱性胰岛素抵抗（FIIR）。结论：RIP140/PRDM16信号通路参与BBR诱导VWAT棕色化的分子机制。     

The effects of beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and tumor necrosis factor-alpha expressions in adipose tissues of obese diabetic KKAy mice

We investigated the effects of beta(3)-adrenoceptor agonist, 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316,243) in obese diabetic KKAy mice. Two weeks' subcutaneous administration of CL-316,243 reduced serum levels of glucose, insulin, triglyceride, free fatty acid and tumor necrosis factor-alpha (TNF-alpha), and increased adiponectin. Adiponectin, adiponectin receptors and beta(3)-adrenoceptor mRNA expressions were reduced in epididymal white adipose tissue in KKAy mice, and CL-316,243 recovered these mRNA expressions. Meanwhile, CL-316,243 suppressed the overexpressed mRNA level of TNF-alpha in both epididymal white adipose tissue and brown adipose tissue. These data suggest that the normalization of adiponectin, adiponectin receptors and TNF-alpha may result in the amelioration of obesity-induced insulin resistance.     

小檗碱调脂作用机制的研究进展

小檗碱是从黄连等植物中提取的一种异喹啉类生物碱,作为传统的抗炎、抑菌药物在临床应用已久。近年来研究发现其具有调脂作用,可通过调节肠道菌群结构、影响胆汁酸的合成与代谢、上调低密度脂蛋白受体(LDLR)的表达、激活内脏脂肪组织相关基因的表达、升高血清脂联素的表达、激活腺苷酸活化蛋白激酶(AMPK)途径、改善胰岛素抵抗等多个作用靶点发挥调脂作用,主要针对小檗碱的调脂作用及其机制进行综述。     

Involvement of adipokines in rimonabant‐mediated insulin sensitivity in ob/ob mice

Objectives It has been recently reported that blockade of type 1 cannabinoid (CB1) receptors by specific antagonists or genetic manipulation alleviates dyslipidaemia, hyperglycaemia and insulin resistance in animal models of obesity and type 2 diabetes. However, the precise role of adipokines in the insulin‐sensitising effects of the CB1 antagonist rimonabant is not clear. Methods ob/ob mice were treated with different doses of rimonabant and then subjected to an oral glucose tolerance test. The expression of different adipokines in white adipose tissue was analysed by quantitative real‐time PCR. Key findings Rimonabant (30 mg/kg) significantly inhibited body weight and fat pad weight gain (P < 0.05) and improved glucose tolerance. Gene expression analysis indicated that tumour necrosis factor‐α, visfatin and retinol binding protein‐4 were downregulated in the adipose tissue of ob/ob mice treated with rimonabant compared with controls, whereas adiponectin was significantly upregulated. Conclusions Rimonabant‐mediated alteration of adipokines in white adipose tissues may play a role in improving insulin sensitivity in obese animals.     

Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice

Adipocyte dysfunction is strongly associated with the development of obesity and insulin resistance. It is accepted that the regulation of adipocytokine expression is one of the most important targets for the prevention of obesity and improvement of insulin sensitivity. In this study, we have demonstrated that anthocyanin (cyanidin 3-glucoside; C3G) which is a pigment widespread in the plant kingdom, ameliorates hyperglycemia and insulin sensitivity due to the reduction of retinol binding protein 4 (RBP4) expression in type 2 diabetic mice. KK-A(y) mice were fed control or control +0.2% of a C3G diet for 5 weeks. Dietary C3G significantly reduced blood glucose concentration and enhanced insulin sensitivity. The adiponectin and its receptors expression were not responsible for this amelioration. C3G significantly upregulated the glucose transporter 4 (Glut4) and downregulated RBP4 in the white adipose tissue, which is accompanied by downregulation of the inflammatory adipocytokines (monocyte chemoattractant protein-1 and tumor necrosis factor-alpha) in the white adipose tissue of the C3G group. These findings indicate that C3G has significant potency in an anti-diabetic effect through the regulation of Glut4-RBP4 system and the related inflammatory adipocytokines.     

Insulin resistance and PPAR insulin sensitizers

Drugs that reverse insulin resistance are of importance as insulin resistance is frequently associated with type 2 diabetes. The three peroxisome proliferator-activated receptors (PPARs) PPARalpha, PPAR90 and PPARgamma are essential for the actions of the many insulin sensitizers. PPARalpha activation enhances free fatty acid oxidation and potentiates anti-inflammatory effects, while PPARgamma is essential for normal adipocyte differentiation and proliferation, as well as fatty acid uptake and storage. Thiazolidinediones (TZDs) are selective ligands of PPARgamma and act as insulin sensitizers. TZDs also suppress free fatty acids via the inhibition of lipolysis in adipose tissue. Insulin sensitizers currently under development include partial PPARgamma agonists and antagonists, and dual PPARalpha/PPARgamma agonists. Given that TZDs show anti-inflammatory, anti-oxidant and antiprocoagulant properties in addition to their insulin sensitizing and antilipotoxic properties, a case may be made for initiating TZD therapy early in the treatment of type 2 diabetes, particularly in those patients at risk of cardiovascular disease. TZDs may also be an important therapeutic option in the treatment of metabolic syndrome.     

2型糖尿病大鼠模型GLUT4 mRNA表达的研究

目的：研究葡萄糖转运体4（GLUT4）mRNA表达在2型糖尿病胰岛素抵抗中的分子机制。方法：采用高脂高糖饲养，一次性腹腔注射链脲佐菌素（STZ）制备2型糖尿病大鼠模型。逆转录聚合酶链反应（RT-PCR）分析大鼠骨骼肌、心肌和脂肪组织中GLUT4 mRNA的表达量变化与差别。结果：正常对照组和2型糖尿病大鼠模型组GLUT4 mRNA在骨骼肌中有相对较高表达，在心肌中表达次之，在脂肪组织中表达相对偏低。2型糖尿病大鼠模型组骨骼肌中GLUT4 mRNA表达量只有对照组骨骼肌的48％、心肌的44％、脂肪组织的38％。结论：GLUT4 mRNA表达量下降导致骨骼肌、心肌和脂肪组织对葡萄糖摄取利用减少是胰岛素抵抗的重要分子基础，是诱发2型糖尿病原因之一。     

Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors, and when activated by their ligands, they induce perixosome proliferation. Three receptors have been identified: PPAR gamma, PPAR delta, and PPAR alpha, all with different tissue expression. PPAR gamma is predominantly expressed in adipose tissue and regulates the formation of fat cells and their function. The effect of PPAR gamma activation is to enhance the action of insulin in insulin-sensitive tissue by increasing peripheral glucose disposal and decreasing hepatic glucose production. The thiazolidinediones (TZDs) are a class of medications used for treatment and possibly the prevention of type 2 diabetes, which are potent agonists for the PPAR gamma receptor. Because the thiazolidinediones target insulin resistance, these agents may improve many of the risk factors associated with obesity and insulin resistance including dyslipidemia, hypertension, impaired fibrinolysis, and atherosclerosis. The impact of the thiazolidinediones on cardiovascular mortality is currently unclear but it appears that the thiazolidinediones exert numerous non-glycemic effects that may improve cardiovascular outcomes. Several non-TZD PPAR gamma agonists and combined PPAR gamma/alpha effect on cardiovascular disease are also being evaluated. These drugs have anti-inflammatory and vascular properties and are currently the subject of numerous studies targeting the primary and secondary prevention of macrovascular disease in patients with diabetes and insulin resistance and might be developed as anti-atherogenic agents on the basis of their actions.     

小檗碱改善2型糖尿病大鼠胰岛素抵抗与PI-3K、GLUT4蛋白相关性的研究

目的观察小檗碱对2型糖尿病大鼠骨骼肌组织磷脂酰肌醇3激酶(phosphatidylinositol-3-kinase,PI-3K)之p85亚基、葡萄糖转运子4(glucose transporter4,GLUT4)蛋白表达的影响,以探讨小檗碱改善胰岛素抵抗,防治2型糖尿病的分子机制。方法采用尾静脉注射小剂量链脲佐菌素(streptozotocin,STZ,30mg.kg-1)加高脂高热量饲料喂养的方法建立2型糖尿病大鼠模型,以小檗碱干预10wk,检测血糖和血清胰岛素,用Western blot方法检测小檗碱干预后2型糖尿病大鼠骨骼肌组织PI-3K之p85亚基、GLUT4蛋白表达水平。结果小檗碱干预的2型糖尿病大鼠骨骼肌组织PI-3K之p85亚基、GLUT4蛋白表达水平均较模型组显著增加。结论小檗碱对2型糖尿病的治疗效应可能与提高骨骼肌组织中PI-3K之p85亚基、GLUT4蛋白表达水平有关。     

Beta 3-adrenergic receptor agonists--past, present and future]

beta 3-Adrenergic receptors (beta 3-AR) play an important role in the thermogenesis in brown adipose tissue and lipolysis in white adipose tissue. beta 3-AR agonists developed in the early stages produced marked weight reduction and an anti-diabetic effect in rats and mice, but did not in humans, because of the difference in the chemical structure of the beta 3-AR. In 1995, a naturally occurring variant (Trp64Arg) of the human beta 3-AR gene was shown to be correlated with obesity and insulin resistance in Pima Indians. Moreover, the fact that white adipocytes produce various hormones and cytokines that cause life-style-related disease was recently made clear. Because the reduction of the visceral fat is thought to be important to prevent these diseases, the expectations for the human beta 3-AR agonist having a novel anti-obesity effect are rising. Some interesting findings were recently reported with beta 3-AR agonists: the difference of the lipolysis was dependent on the existence of the Trp64Arg mutation and the up-regulation effect of the UCP1 and beta 3-ARs themselves in the adipose tissue and skeletal muscle. Therefore, we introduce informations (past, present and future) on beta 3-AR agonists in this paper.     

Cardiovascular disease and PPARdelta: targeting the risk factors

Metabolism, in part, is regulated by the peroxisome proliferator-activated receptors (PPARs). The PPARs act as nutritional lipid sensors and three mammalian PPAR subtypes designated PPARalpha (NR1C1), PPARgamma (NR1C3) and PPARdelta (NR1C2) have been identified. This subgroup of nuclear hormone receptors binds DNA and controls gene expression at the nexus of pathways that regulate lipid and glucose homeostasis, energy storage and expenditure in an organ-specific manner. Recent evidence has demonstrated activation of PPARdelta in the major mass peripheral tissue (ie, adipose and skeletal muscle). It enhances glucose tolerance, insulin-stimulated glucose disposal, lipid catabolism, energy expenditure, cholesterol efflux and oxygen consumption. These effects positively influence the blood-lipid profile. Furthermore, PPARdelta activation produces a predominant type I/slow twitch/oxidative muscle fiber phenotype that leads to increased endurance, insulin sensitivity and resistance to obesity. PPARdelta has rapidly emerged as a potential target in the battle against dyslipidemia, insulin insensitivity, type II diabetes and obesity, with therapeutic efficacy in the treatment of cardiovascular disease risk factors. GW-501516 is currently undergoing phase II safety and efficacy trials in human volunteers for the treatment of dyslipidemia. The outcome of these clinical trials are eagerly awaited against a background of conflicting reports about cancer risks in genetically predisposed animal models. This review focuses on the potential pharmacological utility of selective PPARdelta agonists in the context of risk factors associated with metabolic and cardiovascular disease.     

A novel berberine‐metformin hybrid compound exerts therapeutic effects on obese type 2 diabetic rats

In this study, we investigated the biological activities of a novel berberine‐metformin hybrid compound (BMH473) as an anti‐diabetic agent. BMH473 exhibited significant anti‐hyperglycaemic and anti‐hyperlipidaemic effects on T2DM rats. In white adipose tissue, BMH473 reduced the perirenal and epididymal adipose tissue mass and modulated the lesions in perirenal adipose tissue, by inhibiting the protein expressions of PPAR‐?, C/EBP‐α and SREBP‐1c as well as the mRNA expressions of lipogenic genes. Moreover, BMH473 downregulated the levels of pro‐inflammatory cytokines in perirenal adipose tissue through the suppression of p‐NF‐κB. In liver, BMH473 reduced liver ectopic fat accumulation, by regulating the protein expression levels of SREBP‐1c and PPAR‐α as well as the mRNA expression levels of lipogenic genes. In addition, BMH473 inhibited hepatic gluconeogenesis by promoting the phosphorylation levels of AMPK α and ACC, and down‐regulating the mRNA expression levels of FBPase, G6Pase and PEPCK. Furthermore, BMH473 exhibited significant inhibitory effects on lipogenesis and lipid accumulation in 3T3‐L1 adipocytes by modulating the protein expression levels of PPAR‐?, C/EBP‐α and SREBP‐1 c as well as the mRNA expression levels of lipogenic genes. In conclusion, our results suggest that the newly synthesized BMH473 is beneficial for maintaining glucose and lipid homeostasis in type 2 diabetic rats, and exhibits better anti‐hyperlipidaemic effects compared to metformin and berberine.     

Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin

Berberine can improve insulin resistance, lower blood glucose, and regulate lipid metabolism disorders which cause endothelial dysfunction, leading to vascular complications of type 2 diabetes mellitus. The aim of the present study was to investigate the effects of berberine on endothelial dysfunction of aortas in type 2 diabetes mellitus rats and its mechanism. Wistar rats were randomly divided into four groups: diabetic rats, control rats, diabetic rats treated with berberine (100 mg/kg), and control rats treated with berberine. The serum fasting blood glucose, insulin, total cholesterol, triglyceride and nitric oxide (NO) levels were tested. Acetylcholine-induced endothelium-dependent relaxation and sodium nitroprusside induced endothelium-independent relaxation were measured in aortas for estimating endothelial function. The expression of endothelial nitric oxide synthase (eNOS) mRNA was measured by RT-PCR, and the protein expressions of eNOS and NADPH oxidase (NOX4) were analyzed by western blot. The results showed that berberine significantly decreased fasting blood glucose, and triglyceride levels in diabetic rats. Berberine also improved endothelium-dependent vasorelaxation impaired in aorta. The expressions of eNOS mRNA and protein were significantly increased, while NOX4 protein expression was decreased in aortas from diabetic rats with berberine treatment. Moreover, serum NO levels were elevated after berberine treatment. In conclusion, berberine restores diabetic endothelial dysfunction through enhanced NO bioavailability by up-regulating eNOS expression and down-regulating expression of NADPH oxidase.     

Hypoglycemic effects of Ganoderma lucidum polysaccharides in type 2 diabetic mice

Our aims were to investigate the hypoglycemic effects and mechanisms of action of Ganoderma lucidum polysaccharides (GLPs) administered for 7 days in type 2 diabetic mice. The mice were randomly divided into four groups (8 mice/group): normal control group, diabetic control group, low-dose GLP-treated diabetic group (50 mg/kg/d), and high-dose GLP-treated diabetic group (100 mg/kg/d). Diabetes was induced by streptozotocin injection and high-fat dietary feeding. At the end of the study, fasting serum glucose, insulin, body weight (BW) and epididymal white adipose tissue weight were measured. The hepatic mRNA levels of glycogen phosphorylase (GP), fructose-1,6-bisphosphatase (FBPase), phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) genes were determined by real-time polymerase chain reaction. Both doses of GLPs significantly decreased fasting serum glucose, insulin and epididymal fat/BW ratio compared with the diabetic control group (p < 0.05). The hepatic mRNA levels of GP, FBPase, PEPCK and G6Pase were significantly lower in both GLP-treated groups compared with the diabetic control group. Taken together, GLPs significantly decrease fasting serum glucose levels in type 2 diabetic mice in a dose-dependent manner. The decreases in fasting serum glucose levels may be associated with decreased mRNA expression levels of several key enzymes involved in gluconeogenesis and/or glycogenolysis.